Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$121.17 USD

121.17
978,733

-0.35 (-0.29%)

Updated Apr 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors remain optimistic about QIAGEN (QGEN) backed by the performance of the NGS portfolio and diagnostic solutions.

Tandem Diabetes (TNDM) Gets FDA Nod for Tandem Mobi System

Tandem Diabetes (TNDM) receives FDA clearance for the world's smallest AID system, Tandem Mobi.

Penumbra (PEN) Gains on New Launches Amid Currency Headwind

Penumbra's (PEN) ability to improve net gross margins and EPS amid ongoing inflationary pressure and supply-chain headwinds buoy optimism.

Edwards' (EW) Innovation Aids Growth, Critical Care Flourishes

Edwards' (EW) Surgical Structural Heart sales growth is lifted by the increased adoption of its premium products across all regions.

Sensus Healthcare (SRTS) Expands Global Base With New Pact

The agreement includes the distribution of Sensus Healthcare's (SRTS) SRT-100, SRT-100+ and SR-100 Vision systems, specifically designed for the treatment of non-melanoma skin cancer and keloids.

Bruker (BRKR) Showcases UK Science Investments at EUROMAR 2023

Bruker (BRKR) begins advanced life-science and green-tech research in the United Kingdom.

Quanterix (QTRX) Advances in Alzheimer's Diagnosis With LucentAD

Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with the early signs of AD.

Thermo Fisher (TMO) Announces the Acquisition of CorEvitas

Thermo Fisher's (TMO) acquisition of CorEvitas is likely to strengthen its value proposition.

Here's Why You Should Retain Chemed (CHE) Stock for Now

Investors continue to be optimistic about Chemed (CHE) on the strength of the VITAS Healthcare and Roto-Rooter segments.

ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout

ResMed (RMD) announces the acquisition of the Somnoware diagnostic management platform.

Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker

Abbott (ABT) receives FDA approval for the AVEIR DR leadless pacemaker system, featuring the proprietary i2i technology.

Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover

If this rule is finalized without any changes to reimbursement practices, Myomo's (MYO) MyoPro could be reimbursed in a lump-sum manner by CMS.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Revenue growth across global product categories and a broad geographic footprint bode well for Teleflex (TFX).

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

Investors are optimistic about Zimmer Biomet (ZBH) due to the continued procedure recovery and the strength of emerging markets.

Ensign Group (ENSG) Up 26% in a Year: More Room to Run?

Ensign Group (ENSG) is well-poised for growth on the back of an aging U.S. population, an expanding healthcare portfolio and prudent deployment of capital.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.

Envista (NVST) Gains From New Acquisitions Amid FX Woes

Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.

John Blank headshot

Where Might 2024 Investors Harvest Returns?

One source for those answers: Chief Investment Officers (CIOs).

Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee

Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.

Zimmer Biomet (ZBH) Gains From Procedure Recovery, New Launches

Zimmer Biomet (ZBH) is encouraged about the early positive impact of the Hip Insight launch.

Here's Why You Should Retain National Vision (EYE) Stock Now

Investors continue to remain optimistic about National Vision (EYE) due to the expansion of stores and new investments for the improved optometric experience.

Why You Should Retain Walgreens Boots (WBA) Stock for Now

Investors are optimistic about Walgreens Boots (WBA) on a strong focus on strategic priorities.

Here's Why Investors Should Retain Phibro (PAHC) for Now

Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

Meaningful innovations and strategic alliances boost investors' confidence in SmileDirectClub (SDC).